AVITA Medical, Inc. (RCEL) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR AVITA Medical, Inc. (RCEL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AVITA Medical, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No new risk factors added this quarter; risk profile unchanged since 2024 Annual Report
- • No material updates to existing risks since prior 10-K and Q1 2025 10-Q filings
AVITA Medical, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$17M
▼ -12.7% YoY▼ -7.4% QoQ
Net Income
-$13M
▲ +18.6% YoY▼ -32.9% QoQ
Gross Margin
81.3%
▼ -236bp YoY▲ +16bp QoQ
Operating Margin
-53.6%
▲ +1701bp YoY▲ +690bp QoQ
Net Margin
-77.3%
▲ +562bp YoY▼ -2342bp QoQ
ROE
197.8%
Total Assets
$64M
EPS (Diluted)
$-0.47
▲ +25.4% YoY▼ -27.0% QoQ
Operating Cash Flow
-$5M
▲ +27.7% YoY▲ +49.0% QoQ
Source: XBRL data from AVITA Medical, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on AVITA Medical, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.